Sail Biomedicines is shrinking its crew for the second time this year. | Sail Biomedicines is shrinking its crew for the ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Heartflow is once again looking for a path to go public, with a filing for a Nasdaq IPO. | The former Fierce Medtech Fierce ...

Kennedy Jr. has downplayed the effectiveness of the long-used vaccine and instead promoted the development of new treatments ...

Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

The U.K. is establishing a new biosecurity center designed to improve research into potentially pandemic-causing pathogens ...

To secure the antibody, I-Mab is paying $1.8 million upfront to buy Bridge Health, to be followed by noncontingent quarterly ...

Novartis has ended work on ianalumab in a painful skin condition after the monoclonal antibody failed to meet “predefined ...

Abbott is doubling down on the structural heart space as it aims to gain ground in valve replacements following the recent ...

Otsuka Pharmaceutical is putting down $33 million cash for a Swedish biotech’s IL1RAP antibodies designed to treat autoimmune ...

Patients with a mysterious eye pain disease may be one step closer to seeing the first approved treatment for their condition ...

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...